Abstract
(Abstracted from N Engl J Med 2016;374:738–748)The current standard treatment in first-line chemotherapy regimens for ovarian cancer (OC) is paclitaxel and carboplatin given every 3 weeks. It has been suggested that a dose-dense regimen of paclitaxel administered weekly (involving greater frequency of drug delivery) may enhance its antineoplastic effect.